Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Aug 2015: Trial registered, NCT02521493
  2. 23 Dec 2015: Trial started, NCT02521493

The trials

NCT02521493: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

State
Under way
Phase
Phase 3
People
280 taking part
Started
23 Dec 2015
Primary completion
30 Jun 2024
Arms
Arm B (high risk)
Results
Posted on the registry
  1. 13 Aug 2015: Trial registered
  2. 23 Dec 2015: Trial started
  3. 13 Jun 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.